Testing TS-172 to lower phosphorus in dialysis patients
Treatments studied
Part of Hormones & metabolism, Kidney & urinary clinical trials.
This study tests a new medication called TS-172 for people on dialysis whose phosphorus levels stay high despite taking other phosphorus-lowering drugs. The goal is to see if TS-172 can better control phosphorus and help prevent bone and heart problems that high phosphorus causes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic kidney disease and receive dialysis (hemodialysis or hemodiafiltration) 3 times per week for at least 12 weeks
- You are already taking at least one phosphorus-lowering medication, and your doses haven't changed in the past 4 weeks
- Your blood phosphorus level is between 3.5 and 5.5 mg/dL at screening, then rises to 5.5–10.0 mg/dL within 2 weeks
- You are 18 years or older
- Your parathyroid hormone (PTH) level is 500 pg/mL or lower
- You have not had previous parathyroid surgery or parathyroid intervention
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, TS-172, to lower high phosphorus levels in people with kidney disease who are on hemodialysis. It looks at safety and effectiveness over a longer period.
This trial tests a new medicine called TS-172 for people with high phosphorus levels who are on hemodialysis. It aims to lower phosphorus levels and is taken along with your current phosphate binder medication.
This study tests whether a new medicine called TS-172 can help lower phosphorus levels in patients on peritoneal dialysis (a type of kidney treatment). High phosphorus can cause bone problems and other complications, so the trial aims to see if this drug works better than current treatments.
This study tests how an experimental drug (TS-172) is processed in the body by comparing people with mild to moderate liver disease to those with normal liver function. It may help doctors understand how to dose the drug safely for people with liver problems.
This trial compares two treatment goals for blood phosphate levels in people with end-stage kidney disease who are on dialysis. It may help determine which target is safer and works better in real-world care.
This trial tests a new drug called AP301 to lower high phosphate levels in people on dialysis. It's designed to help control phosphate, which can be hard to manage with diet and current medications.
Hear when a new Hyperphosphatemia Patients on Hemodialysis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.